Recombinetics is a recognized leader in gene editing to advance human and farm animal health and welfare.
Founded in 2008, Recombinetics is a privately held biotechnology company that aims at helping to solve some of the world’s most intractable challenges through gene editing. Recombinetics is delivering viable products and generating revenues today from the large and growing biomedical and agricultural markets.
Recombinetics focused its early-stage development on the application of precision genetic technologies and active patent filings in animals. Development of advanced “gene-editing” technologies for commercial purposes began in 2011. Today, Recombinetics is widely recognized as the leader in livestock gene-editing and associated applied technologies for biomedical research, regenerative medicine, and animal agriculture.
Recombinetics’ first gene-edited animals are generating revenues today with a pipeline of animals under development for the large biomedical and agricultural markets.
Recombinetics is a company built on firsts.
With a robust intellectual property portfolio, RCI leverages its research platform to commercialize and deploy its invented and licensed technologies across key markets.
RCI’s growing global patent portfolio includes 33 issued patents, more than 170 additional applications filed, and first use and enabling patents for livestock for both CRISPR and TALENs.
Here are some of RCI’s achievements in science:
- First gene-edited castration-free swine born
- First gene-edited thermotolerant cattle born
- First gene-edited chickens produced in Europe
- First gene-edited hornless cattle born
- First patent issued in China for gene editing large animals
- First patent issued in Europe for gene editing large animals
- First pig model of congenital heart failure developed
- First pig model of polycystic kidney diseases developed
- First-of-its-kind pig model of Neurofibromatosis Type 1 developed
- First utility patent filed in the US for methods for producing transgenic pigs
- First to make APOBEC pigs for PERV-safe organs
- First DNA transposon engineered pig born
- First gene-edited hornless cattle born
- First to gene-edit for accelerated reproduction OPU in cattle
- First patent issued in the US for CRISPR gene editing in animals optimized to prevent re-cutting of the target sequence
- First to achieve multi-gene editing in pigs and cattle
- First to enable CRISPR in large animals
- First filed CRISPR utility patents in large animals
- First to transfer native allele in species
- First TALENS use to knockout & break genes in embryos
Recombinetics collaborates with public and private leaders to deliver gene-editing solutions.
Some key business highlights include:
- Collaboration with Mayo Clinic announced to develop the first-ever pig model of Osteogenesis Imperfecta
- Recombinetics awarded NIH funding to develop genetically engineered pig more of Glioblastoma
- Alliance to end surgical castration of swine announced precision breeding successes
- Acceligen and Kheiron-Biotech announce joint proects focused on precision breeding
- Collaboration with Mayo Clinic announced to develop cardiomyocytes
- Alliance to end castration of swine announced with collaborators in the United States and the Netherlands
- Alliance to end dehorning of cattle announced with collaborators in Canada; first commercial deal for polled genetics
- Brazil authorities concluded gene-edited dehorned cattle aren’t GMOs
- Target TB announced with collaborators in Ireland and Northern Ireland to curb tuberculosis in cattle
- Collaboration with Mayo Clinic announced to pig model of congenital heart failure
- Collaboration with Children’s Minnesota announced to develop pig model of phenylketonuria
- Announcement of major developments in neurofibromatosis Type 1 model funded by Children’s Tumor Foundation
Our Science is Peer-Reviewed.
Our scientific findings are often published in peer-reviewed scientific journals and often cited by other scientists in their published research. Our work has been documented in over 300 peer-reviewed publications and written been covered many times by both scientific and consumer media outlets.
Here are some of our recent publications:
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
Published in Nature’s Communication Biology
A new tool for mapping breast cancer risk in the tumor microenvironment
Published in Cancer Research
About Cardiovascular Disease
Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model
Published in Translational Research
About Orphan Disease
About Gene Editing and Advanced Reproduction of Pigs
In vivo genome editing using a high-efficiency TALEN system
Published in Nature
Precision editing of large animal genomes
Published in Advances in Genetics
Efficient TALEN-mediated gene knockout in livestock
Published in Proceedings of the National Academy of Sciences
Precise genome editing of PDX1 by direct injection of transcription activator-like effector nucleases (TALENS) into Parthenogenetic Pig Embryos
Published in Reproduction, Fertility and Development
Efficient Nonmeiotic Allele Introgression in Livestock Using Custom Endonucleases
Published in Proceedings of National of the National Academy of Sciences
Simple and efficient methods for enrichment and isolation of endonuclease modified cells
Published in PLOS One
Recombinetics develops and utilizes the best of gene editing technology to improve and lengthen human lives and to improve and grow agriculture to help feed the world’s growing population and reduce animal suffering.
Learn more about the vision and potential of Recombinetics: